FSD Pharma Registered (B) Forum: Community User: Jo74

✌

FSD Pharma and Solarvest Enhance Commitment to CBD Research Project Business Wire (engl.) | 04.02.2020 | 08:30 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma”) and Solarvest BioEnergy Inc. (TSX-V: SVS) (“Solarvest”) (collectively, the “Parties”), are pleased to announce that, further to their press release of May 7, 2019, the Parties have agreed to amendments to the Collaborative Research and Development Agreement (the “Research Agreement”) designed to accelerate progress of the research project that Solarvest is carrying out (the “CBD Research Project”). Under the amended Research Agreement, FSD Pharma has agreed to issue additional class B subordinate voting shares (“FSD Shares”) to Solarvest, which will enable Solarvest to fund the CBD Research Project. In addition, Solarvest has appointed Dr. Edward J. Brennan, Jr., M.D., FACS (“Dr. Brennan”), currently the President of FSD Pharma’s BioSciences Division, to the board of directors of Solarvest. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200203005689/en/ The CBD Research Project involves Solarvest utilizing its algae expression platform to modify algae for the production of pharmaceutical-grade cannabinoids (“Project Cannabinoids”). The Solarvest project is progressing on track and has made progress towards this objective. Since this is a cost-intensive project, and, to enable Solarvest to accelerate the pace of the research, FSD Pharma has issued an additional 225,371 FSD Shares to Solarvest. The Parties have also mutually agreed that Solarvest would benefit from the additional oversight of Dr. Brennan, who brings with him over 25 years of experience in leadership roles at major pharmaceutical companies and clinical research organizations and has a proven track record in drug development. FSD Pharma may realize substantial benefits if the CBD Research Project is successful, as Solarvest is required to grant FSD Pharma an exclusive, worldwide license to develop and commercialize prescription drugs that can treat diseases affecting the central nervous system, and Solarvest will additionally provide FSD Pharma with a royalty fee on the sale or licensing of certain products derived from the Project Cannabinoids.

Servus!

👌🏻

https://www.marijuanamoment.net/bernie-sanders-pledges-legal-marijuana-in-all-50-states-on-day-one-as-president/ Jetzt ist Trump am Zug 🙄

@StockEx, 👍

👌👆Den mag ich

Jens, Die Aktie geht gegen null . ok , deine Meinung aber du gehst allen auf den Sa*k. Nicht nur meine Meinung .

Jens .. such dir bitte ein anderes Forum ! Es geht nicht auf NULL !

Die scheiß Aktie geht gegen 0 Leute

Gerne Fossibär71 ✌ Einfach Geduld haben. Jeder weiß wie langsam Beamte arbeiten bzgl der lizenzen 😂 Und trotzdem regen sich hier die meisten auf, weil die Lizenzen noch nicht da sind... 🦥

https://www.straight.com/news/1354381/cannabis-compound-kills-antibiotic-resistant-superbug

Sky91, Danke....eine gute News! Hilft uns weiter im Bezug auf die Beteiligungen......FSD besitzt 85 Mio. Aktien von Cannara! Zusätzlich kann FSD fast ein 5tel der Anbaufläche dort nutzen (im Bedarfsfall)

Als wenn ich es nicht erwähnt hätte.....Lizenz.......zumindest eine

https://www.newswire.ca/news-releases/cannara-biotech-s-farnham-facility-receives-cultivation-licence-838004302.html

https://www.newswire.ca/news-releases/cannara-biotech-s-farnham-facility-receives-cultivation-licence-838004302.html